The emergence of CRISPR-Cas systems has accelerated the development of gene editing
technologies, which are widely used in the life sciences. To improve the performance of …

The development of new CRISPR–Cas genome editing tools continues to drive major
advances in the life sciences. Four classes of CRISPR–Cas-derived genome editing agents …

CRISPR/Cas9 genome editing has gained rapidly increasing attentions in recent years,
however, the translation of this biotechnology into therapy has been hindered by efficient …

Conventional genome engineering with CRISPR–Cas9 creates double-strand breaks
(DSBs) that lead to undesirable byproducts and reduce product purity. Here we report an …

Genome editing technologies operate by inducing site-specific DNA perturbations that are
resolved by cellular DNA repair pathways. Products of genome editors include DNA breaks …

Eukaryotic cells deploy overlapping repair pathways to resolve DNA damage.
Advancements in genome editing take advantage of these pathways to produce permanent …

Following Cas9 cleavage, DNA repair without a donor template is generally considered
stochastic, heterogeneous and impractical beyond gene disruption. Here, we show that …

Precise gene editing is—or will soon be—in clinical use for several diseases, and more
applications are under development. The programmable nuclease Cas9, directed by a …

Targeted genome editing via engineered nucleases is an exciting area of biomedical
research and holds potential for clinical applications. Despite rapid advances in the field, in …

Clustered regularly interspersed short pallindromic repeats (CRISPR) and CRISPR
associated proteins (Cas) system (CRISPR-Cas) came into light as prokaryotic defence …